Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer

Pharmacogenomics

Volumn 3, Issue 6, 2002, Pages 763-780

  Sarries, Carme ^a   Haura, Eric B ^a   Roig, Barbara ^a   Taron, Miquel ^a   Abad, Albert ^a   Scagliotti, Giorgio ^a   Rosell, Rafael ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

tubulin III; Cisplatin resistance; CPT 11; dUTP nucleotidohydrolase; Epidermal growth factor receptor inhibitors; ERCC1; Gemcitabine resistance; Paclitaxel resistance; Pemetrexed; Plasma homocysteine; Ribonucleotide reductase; Src; STAT signaling pathways; Thymidylate synthase expression; Topoisomerase I inhibitors; TS promoter enhancer region; UGT1A1; Vinorelbine resistance; XRCC1; ZD 1839

Indexed keywords

ANTINEOPLASTIC AGENT; BETA TUBULIN; BIOCHEMICAL MARKER; CARMUSTINE; CISPLATIN; CYTOTOXIC AGENT; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; EDATREXATE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLIC ACID ANTAGONIST; FOLINIC ACID; GEMCITABINE; HOMOCYSTEINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE; RIBONUCLEOTIDE REDUCTASE; STAT PROTEIN; STAT3 PROTEIN; TAXANE DERIVATIVE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; UNINDEXED DRUG;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA REPAIR; DRUG METABOLISM; DRUG RESPONSE; DRUG SENSITIVITY; EXCISION REPAIR; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPERHOMOCYSTEINEMIA; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; METASTASIS; PATIENT CARE; PHARMACOGENOMICS; PREDICTION; PROMOTER REGION; REVIEW; SIGNAL TRANSDUCTION; STOMATITIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PHARMACOGENETICS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036847997     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.3.6.763     Document Type: Review

References (99)

1. Booton R, Thatcher N: Chemotherapy in advanced non small cell lung cancer: indication, intensity and duration. Curr. Opin. Oncol. 14, 191-198 (2002).
2. Rosell R, Monzó M, Alberola V et al.: Determinants of response to cytotoxics. Semin. Oncol. 29(Suppl. 4), 110-118 (2002).
3. Rosell R, Monzo M, O'Brate A, Tarón M: Translational oncogenomics: toward rational therapeutic decision-making. Curr. Opin. Oncol. 14, 171-179 (2002).
4. Buettner R, Mora L B, Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 8, 945-954 (2002).
5. Meyer UA: Pharmacogenetics and adverse drug reactions. Lancet 356, 1667-1671 (2000).
6. Lenz HJ, Leichman CG, Danenberg KD et al.: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J. Clin. Oncol. 14, 176-182 (1995).
7. Leichman GL, Lenz H-J, Leichman L et al.: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol. 15, 3223-3229 (1997).
8. Salonga D, Danenberg KD, Johnson M et al.: Colorectal tumors responding to 5-Fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase and thymidylate phosphorylase. Clin. Cancer Res. 6, 1322-1327 (2000).
9. Huang CL, Yokomise H, Kobayashi S, Fukushima M, Hitomi S, Wada H: Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5FU-based chemotherapy. Int. J. Oncol. 17, 47-54 (2000).
10. Nishimura R, Nagao K, Miyayama H et al.: Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer. Anti-Cancer Res. 19, 5621-5626 (1999).
11. Edler D, Glimelius B, Hallstrom M et al.: Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant 5FU-based chemotherapy. J. Clin. Oncol. 20, 1721-1728 (2002).
12. Allegra CJ, Parr AL, Wold LE et al.: Investigation of the prognostic and predictive value of thymidylate synthase, p53 and Ki- 67 in patients with locally advanced colon cancer. J. Clin. Oncol. 20, 1735-1743 (2002).
13. Adlard JW, Richman SD, Seymour MT, Quirke P: Prediction of response of colorectal cancer to systemic therapy. Lancet Oncol. 3, 75-85 (2002).
14. Ladner RD, Lynch FJ, Groshen S et al.: dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer. Cancer Res. 60, 3493-3503 (2000).
15. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene thymidylate synthase. Cell Struct Funct. 20, 191-197 (1995).
16. Kawakami K, Omura K, Kanehira E, Watanabe Y: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal tumors. Anti-Cancer Res. 19, 3249-3252 (1999).
17. Kawakami K, Salonga D, Park JM et al.: Different length of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res. 7, 4096-4101 (2001).
18. Elsaleh H, Grieu F, Joseph D et al.: Thymidylate synthase genotype and survival benefit from chemotherapy in patients with colorectal cancer. Proc. Am. Soc. Clin. Oncol. 20, 124a, Abstract 493 (2001).
19. Pullarkat ST, Stoelmacher J, Ghaderi V et al.: Human thymidylate synthase gene polymorphism determines response and survival to 5FU chemotherapy. Pharmacogenomics J. 1, 65-70 (2001).
20. Krajinovic M, Costea I, Chiasson S: Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukemia. Lancet 359, 1033-1034 (2002).
21. Rosell R, Crino L: Pemetrexed combination therapy in the treatment of non-small-cell lung cancer. Semin. Oncol. 29, 23-29 (2002).
22. Ulrich CM, Robien K, Sparks R: Pharmacogenetics and folate metabolism - a promising direction. Pharmacogenomics 3(3), 299-313 (2002).
23. Curtis NJ, Hughes AN: Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncol. 2, 298-306 (2001).
24. Lee JS, Libshitz HI, Fossella FV et al.: Improved therapeutic index by leucorovin of edatrexate, cyclophosphamide and cisplatin regimen for non-small-cell lung cancer. J. Natl. Cancer Inst. 84, 1039-1040 (1992).
25. Niyikiza C, Baker SD, Seitz DE et al.: Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther. 1, 545-552 (2002).
26. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstard M, Vollset SE: Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. 337, 230-236 (1997).
27. Mathews NE, Adams MA, Maxwell LR, Gofton TE, Graham CH: Nitric oxide-mediated regulation of chemosensitivity in cancer cells. J. Natl. Cancer Inst. 93, 1879-1885 (2001).
28. Homocysteine lowering trialist collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Br. Med. J. 316, 894-898 (1998).
29. 27 carriers. Clin Cancer Res. 7, 3416-3422 (2001).
30. Goto Y, Yue L, Yokoi A et al.: A novel single polymorphism in the 3′-UTR of the human dihydrofolate reductase gene with enhanced expression. Clin. Cancer Res. 7, 1952-1956 (2001).
31. Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C, Roig B: Molecular targets in the treatment of lung cancer. Cancer Control (2002) (In Press).
32. Lord RVN, Brabender J, Gandara D et al.: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer. Clin. Cancer Res. 8, 2286-2291 (2002).
33. Bosken CH, Wei Q, Amos CI, Spitz MR: An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J. Natl. Cancer Inst. 94, 1091-1099 (2002).
34. Rosell R, Taron M, O'Brate A: Predictive molecular markers in non-small-cell lung cancer. Curr. Opin. Oncol. 13, 101-109 (2001).
35. Monzo M, Taron M, Rosell R Re: Genetic analysis of the β-tubulin gene, TUBB, in non-small-cell lung cancer. J. Natl. Cancer Inst. 94, 774-775 (2002).
36. Rosell R, Taron M, Sarries C, Queralt C, Roig B: β-tubulin mutational analysis: tantalizing findings. Lung Cancer (2002) (In Press).
37. Koh Y, Nishio K: Mechanisms of action of cancer chemotherapeutic agents: topoisomerase inhibitors. In: The Cancer Handbook. MR Alison (Ed.), Nature Publishing Group, London, UK 1313-1322 (2002).
38. Giles FJ, Cortes JE, Thomas DA et al.: Phase I and pharmacokinetic study of DX-8951f (Exatecan Mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin. Cancer Res. 8, 2134-2141 (2002).
39. Douillard JY, Cunningham D, Roth AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastasic colorectal cancer: a multicentre randomised trial. Lancet 355, 1041-1047 (2000).
40. Taron M, Plasencia C, Abad A, Martin C, Guillot M: Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines. Inv. New Drugs 18, 139-147 (2000).
41. Font A, Sanchez JM, Rosell R, Taron M, Martinez E, Manzano JL: Phase I study of weekly CPT-11 (Irinotecan)/Docetaxel in patients with advanced solid tumors. Lung Cancer (2002) (In Press).
42. Ando Y, Saka H, Ando M et al.: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60, 6921-6926 (2000).
43. Font A, Sanchez JM, Taron M et al.: Activity of weekly CPT11 /docetaxel in previously treated non-small-cell lung cancer patients and correlation with UDP-glucuronosyltransferase polymorphisms. (Submitted).
44. Park SY, Lam W, Cheng YC: X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res. 62, 459-465 (2002).
45. Ménissier De Murcia J, Niedergang C, Trucco C et al.: Requirement of poly (ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc. Natl. Acad. Sci. USA 94, 7303-7307 (1997).
46. McBride WH, Dougherty GJ: Molecular mechanisms of radiotherapy. In The Cancer Handbook. MR Alison (Ed.), Nature Publishing Group, London, UK 1359-1369 (2002).
47. Nelson HH, Kelsey KT, Mott LA, Karagas MR: The XRCC1 Arg399Gln polymorphism, sunburn, and nonmelanoma skin cancer: evidence of gene-environment interaction. Cancer Res. 62, 152-155 (2002).
48. Wang H, Wang X, Zhou X-Y et al.: Ku affects the ataxia and Rad3-related/CHK-1 dependent S phase checkpoint response after camptothecin treatment. Cancer Res. 62, 2483-2487 (2002).
49. Saga Y, Mizukami H, Suzuki M et al.: Overexpression of PTEN increases sensitivity to SN38, an active metabolite of topoisomerase I inhibitor irinotecan, in ovarian cancer cells. Clin. Cancer Res. 8, 1248-1252 (2002).
50. Soria JC, Lee H-Y, Lee J et al.: Lack of PTEN expression in non-small-cell lung cancer could be related to promoter methylation. Clin. Cancer Res. 8, 1178-1184 (2002).
51. Rusch V, Baselga J, Cordon-Cardo C et al.: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 53, 2379-2385 (1993).
52. Brabender J, Danenberg KD, Metzger R et al.: Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer Res. 7, 1850-1855 (2001).
53. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E: Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res. 3, 515-522 (1997).
54. Lee M, Draoui M, Zia F et al.: Epidermal growth factor receptor monoclonal antibodies inhibit the growth of lung cancer cell lines. J. Natl. Cancer Inst. Monogr. 13, 117-123 (1992).
55. Ciardiello F, Caputo R, Bianco R et al.: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor- selective tyrosine kinase inhibitor. Clin. Cancer Res. 6, 2053-2063 (2000).
56. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6, 4885-4892 (2000).
57. Norman P: ZD-1839 (AstraZeneca). Curr. Opin. Investig. Drugs 2, 428-234 (2001).
58. Jove R, Hanafusa H: Cell transformation by the viral Src oncogene. Ann. Rev. Cell Biol. 3, 31-56 (1987).
59. Irby RB, Yeatman TJ: Role of Src expression and activation in human cancer. Oncogene 19, 5636-5642 (2000).
60. Odajima J, Matsumura I, Sonoyama J et al.: Full oncogenic activities of v-Src are mediated by multiple signaling pathways; ras as an essential mediator for cell survival. J. Biol. Chem. 275, 24096-24105 (2000).
61. Tice DA, Biscardi JS, Nickles AL, Parsons SJ: Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc. Natl. Acad. Sci. USA 96, 1415-1420 (1999).
62. L expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene 18, 4654-4662 (1999).
63. Irby RB, Mao W, Coppola D et al.: Activating SRC mutation in a subset of advanced human colon cancers. Nat. Genet. 21, 187-190 (1999).
64. Budde RJ, Ke S, Levin VA: Activity of pp60c-src in 60 different cell lines derived from human tumors. Cancer Biochem. Biophys. 14, 171-175 (1994).
65. Mazurenko NN, Kogan EA, Zborovskaya IB, Kisseljov FL: Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur. J. Cancer. 28, 372-377 (1992).
66. Vojtek AB, Der CJ: Increasing complexity of the Ras signaling pathway. J. Biol. Chem. 273, 19925-19928 (1998).
67. Rodriguez-Viciana P, Warne PH, Dhand R et al.: Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370, 527-532 (1994).
68. Peeper DS, Upton TM, Ladha MH et al.: Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 386, 177-181 (1997).
69. Kennedy SG, Wagner AJ, Conzen SD et al.: The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev. 11, 701-713 (1997).
70. Carbone DP: The biology of lung cancer. Semin. Oncol. 24, 388-401 (1997).
71. Brognard J, Clark AS, Ni Y, Dennis PA: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 61, 3986-3997 (2001).
72. Bowman T, Jove R: STAT proteins and cancer. Cancer Control 6, 615-619 (1999).
73. Bowman T, Garcia R, Turkson J, Jove R: STATs in oncogenesis. Oncogene 19, 2474-2488 (2000).
74. Darnell JE, Jr: STATs and gene regulation. Science 277, 1630-1635 (1997).
75. Garcia R, Yu CL, Hudnall A et al.: Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ. 8, 1267-1276 (1997).
76. Garcia R, Jove R: Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J. Biomed. Sci. 5, 79-85 (1998).
77. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE: Stat3 activation is required for cellular transformation by v-Src. Mol. Cell. Biol. 18, 2553-2558 (1998).
78. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R: Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol. 18, 2545-2552 (1998).
79. Shen Y, Devgan G, Darnell JE, Bromberg JF: Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. Proc. Natl. Acad. Sci. USA 98, 1543-1548 (2001).
80. Bromberg JF, Wrzeszczynska MH, Devgan G et al.: Stat3 as an oncogene Cell 98, 295-303 (1999).
81. Kiuchi N, Nakajima K, Ichiba M et al.: STAT3 is required for the gp130-mediated full activation of the c-myc gene. J. Exp. Med. 189, 63-73 (1999).
82. Catlett-Falcone R, Landowski TH, Oshiro MM et al.: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10, 105-115 (1999).
83. Song L, Jove R, Haura EB: Constitutive Stat3 activation in human non-small cell lung cancer cells. EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Conference. Miami, FL, USA Abstract 621 (2001).
84. Yanagawa H, Sone S, Takahashi Y et al.: Serum levels of interleukin 6 in patients with lung cancer. Br. J. Cancer 71, 1095-1098 (1995).
85. Martin F, Santolaria F, Batista N et al.: Cytokine levels (11-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 11, 80-86 (1999).
86. Olivero M, Rizzo M, Madeddu R et al.: Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br. J. Cancer 74, 1862-1868 (1996).
87. Tsao MS, Liu N, Chen JR et al.: Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer 20, 1-16 (1998).
88. Siegfried JM, Weissfeld LA, Singh-Kaw P, Weyant RJ, Testa JR, Landreneau RJ: Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res. 57, 433-439 (1997).
89. Siegfried JM, Weissfeld LA, Luketich JD, Weyant RJ, Gubish CT, Landreneau RJ: The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Ann. Thorac. Surg. 66, 1915-1918. (1998).
90. Ichimura E, Maeshima A, Nakajima T, Nakamura T: Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J. Cancer Res. 87, 1063-1069 (1996).
91. Ryan PD, Chabner BA: On receptor inhibitors and chemotherapy. Clin. Cancer Res. 6, 4607-4609 (2000).
92. Rao GS, Murray S, Ethier SP: Radiosensitization of human breast cancer cells by a novel Erb B family receptor tyrosine kinase inhibitor. Int. J. Radiat. Oncol. Biol. Phys. 48, 1519-1528 (2000).
93. Lei W, Mayotte JE, Levitt ML: EGF-dependent and independent programmed cell death pathways in NCI- H596 nonsmall cell lung cancer cells. Biochem. Biophys. Res. Commun. 245, 939-945 (1998).
94. Lei W, Mayotte JE, Levitt ML: Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells. Anti-Cancer Res. 19, 221-228 (1999).
95. Yu D, Jing T, Liu B et al.: Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell. 2, 581-591 (1998).
96. Canman CE, Gilmer TM, Coutts SB, Kastan MB: Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev. 9, 600-611 (1995).
97. Devary Y, Gottlieb RA, Smeal T, Karin M: The mammalian ultraviolet response is triggered by activation of Src tyrosine kinases. Cell 71, 1081-1091 (1992).
98. Kharbanda S, Yuan ZM, Rubin E, Weichselbaum R, Kufe D: Activation of Src-like p56/p53lyn tyrosine kinase by ionizing radiation. J. Biol. Chem. 269, 20739-20743 (1994).
99. Sinibaldi D, Wharton W, Turkson J, Bowman T, Pledger WJ, Jove R: Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene 19, 5419-5427 (2000).